News from ym biosciences inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 08, 2013, 16:15 ET

Gilead Sciences completes acquisition of YM BioSciences

FOSTER CITY, CA, Feb. 8, 2013 /PRNewswire/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has completed its acquisition of YM...

Feb 07, 2013, 07:19 ET

YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013

MISSISSAUGA, ON, Feb. 7, 2013 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI) (TSX: YM), today reported operational and financial results for...

Feb 05, 2013, 10:47 ET

YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead Sciences

MISSISSAUGA, ON, Feb. 5, 2013 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) (the "Company" or "YM") is pleased to announce that the...

Jan 31, 2013, 11:15 ET

YM BioSciences Shareholders Approve Plan of Arrangement with Gilead Sciences

MISSISSAUGA, ON, Jan. 31, 2013 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) (the "Company" or "YM") is pleased to announce that, at...

Jan 18, 2013, 07:00 ET

YM BioSciences Inc. Plan of Arrangement with Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis

- U.S. Federal Trade Commission and Canadian Competition Bureau also Clear Plan of Arrangement - MISSISSAUGA, ON, Jan. 18, 2013 /PRNewswire/ -...

Dec 21, 2012, 12:19 ET

YM BioSciences Announces Record Date for Previously Announced Plan of Arrangement

MISSISSAUGA, ON, Dec. 21, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today announced that the Supreme Court of Nova Scotia...

Dec 12, 2012, 10:00 ET

Gilead Sciences to Acquire YM Biosciences

- Adds Selective JAK Inhibitor to Growing Oncology and Inflammation Pipeline - FOSTER CITY, CA AND MISSISSAUGA, ON, Dec. 12, 2012 /PRNewswire/...

Dec 09, 2012, 17:15 ET

YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012

- 68% transfusion independence response rate and 37% durable spleen response rate - MISSISSAUGA, ON, Dec. 9, 2012 /PRNewswire/ - YM BioSciences...

Dec 03, 2012, 17:00 ET

YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM

MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its...

Nov 20, 2012, 17:00 ET

YM BioSciences Announces Election of Dr. Kapil Dhingra to its Board of Directors

MISSISSAUGA, ON, Nov. 20, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and...

Nov 09, 2012, 07:00 ET

YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013

MISSISSAUGA, ON, Nov. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and...

Nov 05, 2012, 10:20 ET

YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses

MISSISSAUGA, ON, Nov. 5, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and...

Sep 21, 2012, 07:00 ET

YM BioSciences Reports Fiscal 2012 Operational and Financial Results

- Completed dosing for 166 patient CYT387 Phase I/II nine-month trial - - Completed enrolment of 61 patient CYT387 Phase II BID trial...

May 11, 2012, 09:09 ET

YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012

MISSISSAUGA, ON, May 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse...

Feb 29, 2012, 11:30 ET

YM BioSciences Raises US$80.5 Million from Public Offering

MISSISSAUGA, ON, Feb. 29, 2012 /PRNewswire/ - YM BioSciences Inc. ("YM" or the "Company") (NYSE Amex: YMI; TSX: YM), a drug development company...

Feb 24, 2012, 09:00 ET

YM BioSciences Prices $70 Million Public Offering of Common Shares

MISSISSAUGA, ON, Feb. 24, 2012 /PRNewswire/ - YM BioSciences Inc. ("YM" or the "Company") (NYSE Amex: YMI; TSX: YM), a drug development company...

Feb 23, 2012, 16:01 ET

YM BioSciences Announces Proposed Public Offering of Common Shares

MISSISSAUGA, ON, Feb. 23, 2012 /PRNewswire/ - YM BioSciences Inc. ("YM" or the "Company") (NYSE Amex: YMI; TSX: YM), a drug development company...

Feb 09, 2012, 07:03 ET

YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012

MISSISSAUGA, ON, Feb. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse...

Dec 12, 2011, 17:00 ET

YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011

- Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported - - Well tolerated for dosing periods up to and...

Nov 11, 2011, 07:00 ET

YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2012

MISSISSAUGA, ON, Nov. 11, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge